Simulacra of Data as an Answer | Predictions for 2025
A prediction for the year by Brandi Meyers, vice president of Revenue Operations at MDClone.
The healthcare industry can’t afford to be stagnant. Cost pressures, operational pressures and real human lives are at stake when health innovation is stagnant. The industry needs a better way of moving collaboration and innovation forward.
Meyers
With healthcare data breaches rampant, synthetic data are the answer that research organizations will increasingly look to in 2025 to preserve patient privacy. Synthetic data are artificially created data that [replicate] the statistical characteristics of real-world data but do not contain identifiable information because they use a statistical approach to create a new data set. This allows for safe sharing with accuracy, faster institutional review board [IRB] approvals for research and even the training of AI [artificial intelligence] models with safe starter data stripped of confusing outliers.
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
